NCT06477406View on ClinicalTrials.gov

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Endometriosis
Interventions
DRUG

Cannabidiol

Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.

DRUG

Placebo

An active placebo containing supplemental terpenes matched to the high-CBD product.

Trial Locations (1)

02478

RECRUITING

McLean Hospital, Belmont

All Listed Sponsors
collaborator

Massachusetts Life Sciences Center

UNKNOWN

lead

Mclean Hospital

OTHER